Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Targeting neddylation in cancer therapy.

Duncan K, Schäfer G, Vava A, Parker MI, Zerbini LF.

Future Oncol. 2012 Nov;8(11):1461-70. doi: 10.2217/fon.12.131. Review.

PMID:
23148618
2.

Cullin-RING Ligases as attractive anti-cancer targets.

Zhao Y, Sun Y.

Curr Pharm Des. 2013;19(18):3215-25. Review.

3.

A lysine-to-arginine mutation on NEDD8 markedly reduces the activity of cullin RING E3 ligase through the impairment of neddylation cascades.

Sui Y, Liu Y, Xu G.

Biochem Biophys Res Commun. 2015 Jun 12;461(4):653-8. doi: 10.1016/j.bbrc.2015.04.085. Epub 2015 Apr 24.

PMID:
25918018
4.

Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?

Lamsoul I, Uttenweiler-Joseph S, Moog-Lutz C, Lutz PG.

Biochimie. 2016 Mar;122:339-47. doi: 10.1016/j.biochi.2015.08.003. Epub 2015 Aug 4. Review.

PMID:
26253693
5.

Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.

Zhao Y, Morgan MA, Sun Y.

Antioxid Redox Signal. 2014 Dec 10;21(17):2383-400. doi: 10.1089/ars.2013.5795. Epub 2014 Feb 20. Review.

6.

Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.

Soucy TA, Smith PG, Rolfe M.

Clin Cancer Res. 2009 Jun 15;15(12):3912-6. doi: 10.1158/1078-0432.CCR-09-0343. Epub 2009 Jun 9.

7.

Changes in the ratio of free NEDD8 to ubiquitin triggers NEDDylation by ubiquitin enzymes.

Hjerpe R, Thomas Y, Chen J, Zemla A, Curran S, Shpiro N, Dick LR, Kurz T.

Biochem J. 2012 Feb 1;441(3):927-36. doi: 10.1042/BJ20111671.

8.

The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy.

Soucy TA, Dick LR, Smith PG, Milhollen MA, Brownell JE.

Genes Cancer. 2010 Jul;1(7):708-16. doi: 10.1177/1947601910382898.

9.

SCF E3 ubiquitin ligases as anticancer targets.

Jia L, Sun Y.

Curr Cancer Drug Targets. 2011 Mar;11(3):347-56. Review.

10.

Nedd8 targets ubiquitin ligase Smurf2 for neddylation and promote its degradation.

Shu J, Liu C, Wei R, Xie P, He S, Zhang L.

Biochem Biophys Res Commun. 2016 May 20;474(1):51-56. doi: 10.1016/j.bbrc.2016.04.058. Epub 2016 Apr 13.

PMID:
27086113
11.

Overactivated neddylation pathway as a therapeutic target in lung cancer.

Li L, Wang M, Yu G, Chen P, Li H, Wei D, Zhu J, Xie L, Jia H, Shi J, Li C, Yao W, Wang Y, Gao Q, Jeong LS, Lee HW, Yu J, Hu F, Mei J, Wang P, Chu Y, Qi H, Yang M, Dong Z, Sun Y, Hoffman RM, Jia L.

J Natl Cancer Inst. 2014 May 22;106(6):dju083. doi: 10.1093/jnci/dju083. Print 2014 Jun.

PMID:
24853380
12.

SCCRO (DCUN1D1) is an essential component of the E3 complex for neddylation.

Kim AY, Bommeljé CC, Lee BE, Yonekawa Y, Choi L, Morris LG, Huang G, Kaufman A, Ryan RJ, Hao B, Ramanathan Y, Singh B.

J Biol Chem. 2008 Nov 28;283(48):33211-20. doi: 10.1074/jbc.M804440200. Epub 2008 Sep 30.

13.

Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy.

Tanaka T, Nakatani T, Kamitani T.

Mol Oncol. 2012 Jun;6(3):267-75. doi: 10.1016/j.molonc.2012.01.003. Epub 2012 Jan 21. Review.

14.

The covalent modifier Nedd8 is critical for the activation of Smurf1 ubiquitin ligase in tumorigenesis.

Xie P, Zhang M, He S, Lu K, Chen Y, Xing G, Lu Y, Liu P, Li Y, Wang S, Chai N, Wu J, Deng H, Wang HR, Cao Y, Zhao F, Cui Y, Wang J, He F, Zhang L.

Nat Commun. 2014 May 13;5:3733. doi: 10.1038/ncomms4733.

PMID:
24821572
15.

Rbx1 flexible linker facilitates cullin-RING ligase function before neddylation and after deneddylation.

Liu J, Nussinov R.

Biophys J. 2010 Aug 4;99(3):736-44. doi: 10.1016/j.bpj.2010.05.021.

16.

Destabilization of CDC6 upon DNA damage is dependent on neddylation but independent of Cullin E3 ligases.

Tan CY, Hagen T.

Int J Biochem Cell Biol. 2013 Jul;45(7):1489-98. doi: 10.1016/j.biocel.2013.04.010. Epub 2013 Apr 15.

PMID:
23597704
17.

E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.

Masumoto K, Kitagawa M.

Curr Cancer Drug Targets. 2016;16(2):130-5. Review.

PMID:
26560119
18.

NEDD4: a promising target for cancer therapy.

Ye X, Wang L, Shang B, Wang Z, Wei W.

Curr Cancer Drug Targets. 2014;14(6):549-56. Review.

19.

Role of E3 ubiquitin ligases in gastric cancer.

Hou YC, Deng JY.

World J Gastroenterol. 2015 Jan 21;21(3):786-93. doi: 10.3748/wjg.v21.i3.786. Review.

20.

HIV relies on neddylation for ubiquitin ligase-mediated functions.

Nekorchuk MD, Sharifi HJ, Furuya AK, Jellinger R, de Noronha CM.

Retrovirology. 2013 Nov 18;10:138. doi: 10.1186/1742-4690-10-138.

Supplemental Content

Support Center